Impact of acute kidney injury on mortality and medical costs in patients with meticillin-resistant Staphylococcus aureus bacteraemia: A retrospective, multicentre observational study

Journal of Hospital Infection

Volumn 83, Issue 4, 2013, Pages 300-306

  Joo, E J ^a   Peck, K R ^a   Ha, Y E ^a   Kim, Y S ^b   Song, Y G ^c   Lee, S S ^d   Ryu, S Y ^e   Moon, C ^f   Lee, C S ^g   Park, K H ^h  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Hallym University   (South Korea)

^e Keimyung University   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h Chonnam National University Medical School   (South Korea)

Author keywords

Acute kidney injury; Costs; Meticillin resistance; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CATHETER INFECTION; FEMALE; HEALTH CARE COST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SOUTH KOREA;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS;

EID: 84875408362     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2012.12.008     Document Type: Article

References (28)

1. Acar J.F. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 1997, 24(Suppl. 1):S17-18.
2. Naimi T.S., LeDell K.H., Como-Sabetti K., et al. Comparison of community- and health care-associated meticillin-resistant Staphylococcus aureus infection. JAMA 2003, 290:2976-2984.
3. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with meticillin-resistant and meticillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
4. Rubio-Terres C., Garau J., Grau S., Martinez-Martinez L. Cost of bacteraemia caused by meticillin-resistant vs. meticillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect 2010, 16:722-728.
5. Kim J.M., Park E.S., Jeong J.S., et al. Multicenter surveillance study for nosocomial infections in major hospitals in Korea. Nosocomial Infection Surveillance Committee of the Korean Society for Nosocomial Infection Control. Am J Infect Control 2000, 28:454-458.
6. Kim H.B., Jang H.C., Nam H.J., et al. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob Agents Chemother 2004, 48:1124-1127.
7. Park E.J., Kim N.J., Song J.H., Woo J.H., Cheong H.S., et al. Analysis of economic outcomes of meticillin-resistant Staphylococcus aureus bacteremia using retrospective case-control study. Korean J Clin Pharmacol 2007, 17:59-64.
8. Bates D.W., Su L., Yu D.T., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001, 32:686-693.
9. Jeffres M.N., Isakow W., Doherty J.A., Micek S.T., Kollef M.H. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated meticillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 29:1107-1115.
10. Shen W.C., Chiang Y.C., Chen H.Y., et al. Nephrotoxicity of vancomycin in patients with meticillin-resistant Staphylococcus aureus bacteraemia. Nephrology (Carlton) 2011, 16:697-703.
11. Kalil A.C., Murthy M.H., Hermsen E.D., Neto F.K., Sun J., Rupp M.E. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010, 38:1802-1808.
12. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.
13. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
14. Barrantes F., Tian J., Vazquez R., Amoateng-Adjepong Y., Manthous C.A. Acute kidney injury criteria predict outcomes of critically ill patients. Crit Care Med 2008, 36:1397-1403.
15. Chertow G.M., Burdick E., Honour M., Bonventre J.V., Bates D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16:3365-3370.
16. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136-141.
17. Smith G.L., Vaccarino V., Kosiborod M., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail 2003, 9:13-25.
18. Dasta J.F., Kane-Gill S.L., Durtschi A.J., Pathak D.S., Kellum J.A. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008, 23:1970-1974.
19. Lassnigg A., Schmidlin D., Mouhieddine M., et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004, 15:1597-1605.
20. Harbarth S., Burke J.P., Lloyd J.F., Evans R.S., Pestotnik S.L., Samore M.H. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002, 35:e120-127.
21. Oliveira J.F., Silva C.A., Barbieri C.D., Oliveira G.M., Zanetta D.M., Burdmann E.A. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother 2009, 53:2887-2891.
22. Paul M., Kariv G., Goldberg E., et al. Importance of appropriate empirical antibiotic therapy for meticillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2010, 65:2658-2665.
23. Rodriguez-Bano J., Millan A.B., Dominguez M.A., et al. Impact of inappropriate empirical therapy for sepsis due to health care-associated meticillin-resistant Staphylococcus aureus. J Infect 2009, 58:131-137.
24. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of meticillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
25. Neville L.O., Brumfitt W., Hamilton-Miller J.M., Harding I. Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Int J Antimicrob Agents 1995, 5:187-193.
26. Svetitsky S., Leibovici L., Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009, 53:4069-4079.
27. Hermsen E.D., Hanson M., Sankaranarayanan J., Stoner J.A., Florescu M.C., Rupp M.E. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010, 9:9-14.
28. McKinnon P.S., Sorensen S.V., Liu L.Z., Itani K.M. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006, 40:1017-1023.